Research Library / Tissue Research / ARA-290
Tissue Research researchARA-290 (Cibinetide)
Cibinetide · Helix-B surface peptide
Designed to engage tissue-protective signaling without substantial red-blood-cell stimulation. The listed community example (common short research schedule) describes 4 mg per administration, once daily, via subcutaneous; this is not a validated dosing recommendation. An illustrative 10 mg vial at an assumed 1 mL final volume yields 10 mg/mL; diluent compatibility remains product-specific. For research and education only, not personal medical guidance.
Quick Reference
- Example vial
- 10mg
- Assumed final volume
- 1mL · not an amount to add
- Concentration
- 10mg/mL · conditional arithmetic
- One U-100 marking
- 100mcg in 0.01 mL
Hypothetical vial math does not reproduce a study formulation or verify a diluent, sterility or storage period.
Research schedules
4 mg · subcutaneous · once daily · 28 days
Adults with sarcoidosis-associated small-fiber neuropathyMolecular Medicine, 2014| Context / phase | Amount | Schedule total | Frequency | Timing | Route | Evidence |
|---|---|---|---|---|---|---|
| Common short research schedule | 4 mg | 4 mg/day | Once daily | Consistent daily time | Subcutaneous | Community-reported |
Repeated community reports do not establish identity, safety, effectiveness or an appropriate exposure. Component schedules do not validate a same-vial blend.
Vial calculator
Linked to Quick Reference and compatible supply calculations.
Read the needle-side edge of the black stopper. Liquid tint is illustrative.
Scale illustration · one U-100 marking = 0.01 mL.
Arithmetic yield at this example amount
2.5 example portions per vial
2 full amounts; 2 mg remaining. Yield is not a storage or reuse period.
See the calculation
Concentration = vial content ÷ final volume. Volume = example amount ÷ concentration. U-100 markings = mL × 100.
Original example & formulation context
4 mg arithmetic example · 10 mg/mL · 0.4 mL · 40 units
10 mg in a hypothetical 1 mL final solution gives 10 mg/mL; 4 mg calculates to 0.40 mL or 40 U-100 units. This does not establish that the vial will dissolve or remain stable at this concentration. Check buffer/excipients and product-specific diluent instructions before preparation. PBS and water added to prebuffered vials are not equivalent methods; no universal PBS/BAC ratio is established. See the preparation notes below.
Supplies & vial yield
10 mg (hypothetical) · 1 mL final solution (arithmetic only; diluent not selected) · Common short research schedule
Vial counts and final solution totals below use the selected 10 mg example at 1 mL. The original schedule totals stay unchanged.
Schedule phases used for planning
| Phase | Amount | Frequency | Weekly total |
|---|---|---|---|
| Selected planning schedule | 4 mg | Once daily | 28 mg/week |
Peptide vials
| Horizon | Total | Vials* |
|---|---|---|
| 4 weeks | 112 mg | 12 × 10 mg |
| 8 weeks | 224 mg | 23 × 10 mg |
| 12 weeks | 336 mg | 34 × 10 mg |
Liquid planning
| Horizon | Final volume* | Diluent supplies |
|---|---|---|
| 4 weeks | Product-specific; verify buffer | Not established |
| 8 weeks | Product-specific; verify buffer | Not established |
| 12 weeks | Product-specific; verify buffer | Not established |
Administration count
| Horizon | Administrations |
|---|---|
| 4 weeks | 28 |
| 8 weeks | 56 |
| 12 weeks | 84 |
Original schedule counts. Check the calculated volume against syringe capacity; no split-dose technique is assigned.
Original vial-life context
4 weeks: 2.5 administrations
8 weeks: 2.5 administrations
12 weeks: 2.5 administrations
Applies to the original planning basis above; not a product stability period.
ARA-290 vial counts are arithmetic only. Diluent supplies are not specified because buffer/excipients and preparation requirements must be verified for the actual product. Ranges reflect the low and high ends of the selected displayed schedule (community-reported). Vials are rounded up; one new U-100 syringe is counted per subcutaneous administration. Liquid totals are conditional final solution volumes, not verified quantities to add. Diluent bottle counts are withheld pending product-specific preparation instructions. Arithmetic does not establish storage or reuse periods.
*Conditional mass and final-volume arithmetic. No stability, sterility, safe reuse period or verified diluent quantity is established. Cleansing materials, sterile supplies, labels and sharps disposal follow the actual research procedure.
Protocol overview & research context
- Identity
- ARA-290 · Cibinetide · Helix-B surface peptide
- Evidence / status
- Phase II. Investigational — not FDA approved
- Clinical route, frequency & duration
Sarcoidosis neuropathy trial: 4 mg · subcutaneous · once daily · 28 days
- Community purpose
- Neuropathic discomfort, inflammation, and tissue-protection or recovery discussions.
Loading, titration and maintenance
A separate loading phase is not identified in this library entry. Titration, maintenance and stopping rules depend on the specific product or study; a listed range is not automatically an escalation plan.
Reconstitution & formulation
PBS is reported for unbuffered research powder. Published animal methods used PBS. Human trial preparations were formulation-specific; one protocol used a vial already containing phosphate buffer (pH 6.5), sucrose and mannitol, reconstituted with sterile Water for Injection.
Other vehicles and approaches discussed
Community reports describe PBS alone, PBS with bacteriostatic water, and water added to already-buffered vials. These are different preparations. No universal PBS/BAC ratio or comparative anti-gelling method was validated in the sources reviewed on October 20, 2026.
- Evidence context
- Conflicting reports; buffer already in the vial may matter
- Cloudiness / gel signal
- Recurrent clouding / incomplete dissolution; gel-like material also reported
- Product details to verify
- Check the actual vial's buffer and excipient content, salt form, concentration, pH and product instructions. These may contribute to differing reports; the cause and incidence of gelling have not been established by a comparative study.
PBS use in a study does not prove every vial requires added PBS, and a prebuffered trial vial does not validate water alone for unbuffered powder. Laboratory PBS is not automatically an injectable-grade diluent. Adding BAC changes buffer and preservative concentrations; clarity does not establish sterility, stability or suitability. Do not attempt to rescue cloudy or gelled material.
Preparation documentation checklist
- Confirm identity, nominal content, salt form, buffer and excipients.
- Verify the actual product's diluent, amount to add and intended method.
- Calculate concentration from final solution volume, and cross-check units.
- Record lot, concentration, diluent, preparation date, storage and discard instructions.
This checklist does not replace a validated preparation procedure.
Storage, clarity & stability
- Unopened product
- Follow its documented temperature, light protection, shipping and expiration requirements.
- Prepared material
- Chemical stability and microbial safety are formulation-specific. A diluent bottle's discard period does not establish the compound's storage period.
- Visible-change context
- Recurrent clouding / incomplete dissolution; gel-like material also reported
Unexpected cloudiness, particles or gel
For a product intended to form a clear solution, do not use or attempt to salvage unexpected persistent clouding, strings, precipitate, thickening or gel. Labeled suspensions, including some triptorelin depots, have their own expected appearance and instructions.
Why vial yield does not establish shelf life
Arithmetic portions assume the material remains usable. Chemical degradation, contamination, handling losses and required discard limits may reduce practical yield. Freezing, warming, acidifying or further diluting cannot be assumed to restore quality.
No universal refrigerated, room-temperature or 90-day beyond-use period is assigned by the calculator.
How it works
Innate repair receptor agonist derived from erythropoietin
Designed to engage tissue-protective signaling without substantial red-blood-cell stimulation. Buffer and excipient content must be checked before choosing a diluent: community reports describe clouding, poor dissolution and gel-like material with some preparations.
Community-reported purpose
Neuropathic discomfort, inflammation, and tissue-protection or recovery discussions.
Reported purposes and marketing use-cases are not an approved indication or proof of efficacy.
Clinical findings & study landscape
Sarcoidosis neuropathy trial
Protocol: 4 mg · subcutaneous · once daily · 28 days
Population: Adults with sarcoidosis-associated small-fiber neuropathy
Read the cited evidenceFindings apply to the tested product, population and methods. A registry listing, mechanistic study or evidence-landscape link is not itself proof of efficacy or validation of an online vial.
Safety, evidence limits & regulatory status
Compound-specific safety context
Small studies cannot define long-term safety; results from one disease population should not be generalized.
Development and regulatory status
Investigational — not FDA approved
Approval of a named product does not extend to every vial, formulation, route, blend or indication carrying a related name.
What this guide cannot establish
The library does not authenticate a product or determine a personal starting dose, missed-dose rule, restart regimen, interaction plan or combination protocol. Study schedules, community reports and vial calculations retain separate evidence labels.
Frequently asked questions
What is ARA-290?
Designed to engage tissue-protective signaling without substantial red-blood-cell stimulation. Buffer and excipient content must be checked before choosing a diluent: community reports describe clouding, poor dissolution and gel-like material with some preparations.
Innate repair receptor agonist derived from erythropoietin
Does vial strength mean the amount per administration?
No. A vial's label states nominal contents. The amount used in a study belongs to its assigned product and protocol. Changing vial strength changes concentration and yield, not the study's assigned amount.
Why does changing final volume change the U-100 value?
A larger final volume reduces concentration for the same mass. U-100 markings are volume measurements: one marking equals 0.01 mL. They are not biological international units of a peptide.
What happens when a calculation exceeds one syringe or vial?
Available mass and syringe capacity are separate limits. The calculator flags a result above 1 mL; it does not provide a splitting or combining technique.
Is there a loading phase or standard cycle?
A separate loading phase is not identified in this entry. Do not infer one from a range of reported amounts.
Cycle length is not established as a universal protocol.
Which diluent and storage period should this material use?
PBS is reported for unbuffered research powder. Published animal methods used PBS. Human trial preparations were formulation-specific; one protocol used a vial already containing phosphate buffer (pH 6.5), sucrose and mannitol, reconstituted with sterile Water for Injection.
Calculation examples do not establish solvent compatibility, sterility or shelf life.
Where do I track or calculate a multi-phase schedule?
The Free Planner supports saved research examples and multi-phase planning. This guide's calculator is local to the page and does not save a protocol automatically.
Open Free PlannerReferences & evidence trail
- Clinical / regulatory / evidence landscapeMolecular Medicine, 2014: Sarcoidosis neuropathy trial
- Human trial protocol, July 6, 2017 — section 9.1, prebuffered vial
- Animal study, 2014 — PBS in treatment methods
- Community report — buffered versus unbuffered vials (anecdotal)
- Community report — cloudiness after BAC water (anecdotal)
- Community discussion — PBS/BAC conflicts and gel-like reports (anecdotal)
Clinical sources remain attached to their studies; laboratory and community formulation sources retain their own limits. Preparation review dates do not imply that every clinical study was newly reviewed today.
Independent educational research reference. Not medical advice or an individualized dosing recommendation.